Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) has a beta value of 0.66 and has seen 6.02 million shares traded in the last trading session. The company, currently valued at $37.88M, closed the last trade at $0.66 per share which meant it gained $0.01 on the day or 1.00% during that session. The SONN stock price is -416.67% off its 52-week high price of $3.41 and 16.67% above the 52-week low of $0.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 27.57 million shares traded. The 3-month trading volume is 8.03 million shares.
The consensus among analysts is that Sonnet BioTherapeutics Holdings Inc. (SONN) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) trade information
Sporting 1.00% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the SONN stock price touched $0.66 or saw a rise of 17.5%. Year-to-date, Sonnet BioTherapeutics Holdings Inc. shares have moved -70.51%, while the 5-day performance has seen it change 13.91%. Over the past 30 days, the shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) have changed -37.95%. Short interest in the company has seen 0.53 million shares shorted with days to cover at 0.3.
Wall Street analysts have a consensus price target for the stock at $8.00, which means that the shares’ value could jump 91.75% from current levels. The projected low price target is $8.00 while the price target rests at a high of $8.00. In that case, then, we find that the current price level is -1112.12% off the targeted high while a plunge would see the stock gain -1112.12% from current levels.
Sonnet BioTherapeutics Holdings Inc. (SONN) estimates and forecasts
The company’s shares have lost -68.38% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 45.70% over the past 5 years.
Sonnet BioTherapeutics Holdings Inc. is expected to release its next earnings report between August 12 and August 16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)’s Major holders
Insiders own 8.80% of the company shares, while shares held by institutions stand at 3.44% with a share float percentage of 3.77%. Investors are also buoyed by the number of investors in a company, with Sonnet BioTherapeutics Holdings Inc. having a total of 24 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 0.26 million shares worth more than $0.58 million. As of Mar 30, 2021, Blackrock Inc. held 1.21% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 0.14 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $0.31 million and represent 0.64% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Micro Cap ETF. As of Mar 30, 2021, the former fund manager holds about 0.64% shares in the company for having 0.14 million shares of worth $0.31 million while later fund manager owns 45126.0 shares of worth $0.11 million as of Apr 29, 2021, which makes it owner of about 0.21% of company’s outstanding stock.